As the saying goes, everything’s bigger in Texas—including Johnson & Johnson Innovation LLC’s newest offshoot, JLABS @ TMC, which opens its doors this week at the Texas Medical Center in Houston.
The 34,000-square-foot life sciences incubator—the fifth JLABS facility to debut in the U.S.—will provide up to 50 up-and-coming startups innovating in the heathcare space with everything from private offices to modular laboratory suites decked out with state-of-the-art equipment.
“JLABS @ TMC enhances our already robust ecosystem of talented entrepreneurs who are solving the greatest unmet healthcare needs of our generation,” said Robert C. Robbins, M.D., president and CEO of the Texas Medical Center. “TMC has spent decades making healthcare history, and now these [startups] housed at TMC will take innovation to new heights.”
So what is it like to actually work inside such an innovative space? read more
Ixekizumab Demonstrates Rapid, Clinically Meaningful Improvements as Early as One Week among Patients with Moderate-to-Severe Plaque Psoriasis
PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that treatment for moderate-to-severe plaque psoriasis with ixekizumab resulted in clinically meaningful improvements as early as one week, compared to patients treated with etanercept or placebo. Detailed results of this combined analysis of UNCOVER-2 and UNCOVER-3 were presented during the American Academy of Dermatology (AAD) Annual Meeting taking place March 4-8 in Washington, D.C.
UNCOVER-2 and UNCOVER-3 are double-blind, multicenter, Phase 3 studies evaluating more than 2,500 patients with moderate-to-severe plaque psoriasis across 19 countries. In these comparator studies, patients were assigned to receive either placebo, etanercept (50 mg twice a week) or ixekizumab (80 mg every two or four weeks) for 12 weeks, following a 160-mg starting dose.
This combined analysis evaluated the speed of onset of clinical improvement as measured by mean percentage improvement in Psoriasis Area Severity Index (PASI) score from baseline, as well as time to PASI 50 and PASI 75 among patients treated with ixekizumab, etanercept or placebo. PASI measures the extent and severity of psoriasis by assessing average redness, thickness and scaliness of skin lesions (each graded on a zero to four scale), weighted by the body surface area of involved skin. read more
Moberg Pharma divests three brands for $10.0 million
Moberg Pharma AB (OMX: MOB) announces that the company has entered into an agreement with Strides Pharma Inc. to divest the brands Jointflex, Fergon and Vanquish for a total consideration of $10 million plus the inventory value at closing.
Moberg Pharma’s strategy is to build value through profitable growth of strategic brands, increasing the value of pipeline assets and acquisitions.
Divesting the three brands enables Moberg Pharma to focus on its core business. The three divested brands had total net sales of $6.1 million in 2015 and originated from earlier acquisitions where the primary purpose was to acquire strategic assets in specialty skin care. The divestment results in a capital gain of $3 million.
The transaction is expected to close within the next four weeks.
“We are pleased with the agreement with Strides which enables us to further focus on our strategic assets and M&A activities. The transaction also results in a capital gain for our shareholders”, says Peter Wolpert, CEO Moberg Pharma.
Gilead Sciences Announces Settlement Method for 1.625% Convertible Senior Notes Due 2016 –
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has elected to settle its conversion obligations in connection with any 1.625% Senior Convertible Notes due 2016 (the “Notes”) submitted for conversion on or after February 1, 2016 entirely in cash.
In accordance with the foregoing, Gilead notified Wells Fargo Bank, National Association, the Trustee for the Notes, that it had designated a “Cash Percentage” (as defined in the indenture governing the Notes (the “Indenture”)) of 100% to apply to the “Daily Share Amount” for every “Trading Day” during the relevant “Conversion Reference Period” (each as defined in the Indenture) applicable to the Notes.
Aimmune Therapeutics Announces Phase 2 Follow-On Study of AR101 for the Treatment of Peanut Allergy Demonstrated Increased Desensitization and Improved Tolerability with Low-Dose Maintenance
LOS ANGELES–(EON: Enhanced Online News)–Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™(characterized oral desensitization immunotherapy) treatments for life-threatening food allergies, today announced data from the open-label ARC002 Phase 2 trial of its lead product candidate, AR101 for the treatment of peanut allergy. All patients who completed 12 weeks of low-dose maintenance therapy were desensitized to levels of peanut protein beyond the 250-300 mg typically found in one peanut kernel. read more
Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor
HENDERSON, Nev.–(BUSINESS WIRE)–Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the Company has initiated the planned Phase 2 clinical study for Poziotinib, its novel pan-HER inhibitor. The Phase 2 trial is an open-label study that will enroll approximately 70 patients with HER2-positive metastatic breast cancer, who have failed at least two prior HER2-directed therapies. read more
Bristol-Myers Squibb and LabCentral Team Up in Cambridge, Massachusetts to Support Promising Biotech Startup Companies
NEW YORK & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and LabCentral, an innovative, shared laboratory space designed as a launch pad for life-sciences and biotech startups, today announced an agreement in which Bristol-Myers Squibb has become a LabCentral platinum sponsor. As part of the agreement, Bristol-Myers Squibb can nominate up to two innovative life-sciences and biotech startup companies per year to take up residence in LabCentral’s Kendall Square facilities. The 2016 nomination process for Bristol-Myers Squibb-sponsored Golden Tickets will launch by the end of the first quarter. read more
Alvogen Announces Acquisition to Expand U.S. Business
PINE BROOK, N.J.–(BUSINESS WIRE)–Alvogen announced today that it has signed a definitive agreement to acquire County Line Pharmaceuticals (“County Line”), a specialty generic pharmaceutical company based in Wisconsin, U.S. The transaction price is not disclosed.
Founded in 2007, County Line focuses on under-appreciated generic assets and specialty generic products. It has a balanced portfolio that spans multiple dosage forms including oral solutions, creams, ointments, gels and orally disintegrating tablets with 12 marketed products in the U.S. and leading positions across all its commercial product areas. In addition, it has a well-diversified pipeline, with 9 approvals and launches expected in 2016 and 8 more approvals in 2017, supported by a strong medium-term pipeline. County Line has a proven track record of high quality and consistent supply, supported by a reliable supply chain.
Quintiles Named as a 2016 World’s Most Ethical Company by the Ethisphere Institute
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Quintiles, the world’s largest provider of product development and integrated healthcare services, has been recognized by the Ethisphere Institute, a global leader in defining and advancing the standards of ethical business practices, as a 2016 World’s Most Ethical Company®.
PeptiDream Announces License of PDPS Technology to Lilly
TOKYO–(BUSINESS WIRE)–PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today that it has entered into a Technology License Agreement with U.S.-based Eli Lilly and Company (Lilly, NYSE: LLY) to nonexclusively license PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology. Under the terms of the Technology License Agreement, PeptiDream will receive upfront and annual technology access payments, and will be eligible to receive development milestones and royalties on future sales of products (both peptide and small molecule therapeutics) that arise from use of the PDPS technology. Similar to previous technology licenses, the license will exclude work on peptide-drug conjugate (PDC) programs, as PeptiDream has extensive internal development efforts ongoing in this area, to which PeptiDream will be providing additional information soon.